Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models.
Hindocha S, Charlton TG, Linton-Reid K, Hunter B, Chan C, Ahmed M, Robinson EJ, Orton M, Ahmad S, McDonald F, Locke I, Power D, Blackledge M, Lee RW, Aboagye EO. Hindocha S, et al. Among authors: power d. EBioMedicine. 2022 Mar;77:103911. doi: 10.1016/j.ebiom.2022.103911. Epub 2022 Mar 3. EBioMedicine. 2022. PMID: 35248997 Free PMC article.
Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.
Sharma R, Mapelli P, Hanna GB, Goldin R, Power D, Al-Nahhas A, Merchant S, Ramaswami R, Challapalli A, Barwick T, Aboagye EO. Sharma R, et al. Among authors: power d. EJNMMI Res. 2016 Dec;6(1):81. doi: 10.1186/s13550-016-0234-3. Epub 2016 Nov 16. EJNMMI Res. 2016. PMID: 27854031 Free PMC article.
Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients.
Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, Scarsbrook A, McDermott G, Cook GJ, Landau D, Chua S, O'Connor R, Dickson J, Power DA, Barwick TD, Rockall A, Aboagye EO. Arshad MA, et al. Among authors: power da. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):455-466. doi: 10.1007/s00259-018-4139-4. Epub 2018 Sep 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30173391 Free PMC article.
Gross tumour volume radiomics for prognostication of recurrence & death following radical radiotherapy for NSCLC.
Hindocha S, Charlton TG, Linton-Reid K, Hunter B, Chan C, Ahmed M, Greenlay EJ, Orton M, Bunce C, Lunn J, Doran SJ, Ahmad S, McDonald F, Locke I, Power D, Blackledge M, Lee RW, Aboagye EO. Hindocha S, et al. Among authors: power d. NPJ Precis Oncol. 2022 Oct 27;6(1):77. doi: 10.1038/s41698-022-00322-3. NPJ Precis Oncol. 2022. PMID: 36302938 Free PMC article.
Author Correction: Gross tumour volume radiomics for prognostication of recurrence & death following radical radiotherapy for NSCLC.
Hindocha S, Charlton TG, Linton-Reid K, Hunter B, Chan C, Ahmed M, Greenlay EJ, Orton M, Bunce C, Lunn J, Doran SJ, Ahmad S, McDonald F, Locke I, Power D, Blackledge M, Lee RW, Aboagye EO. Hindocha S, et al. Among authors: power d. NPJ Precis Oncol. 2022 Nov 23;6(1):87. doi: 10.1038/s41698-022-00332-1. NPJ Precis Oncol. 2022. PMID: 36418522 Free PMC article. No abstract available.
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitis.
Hindocha S, Hunter B, Linton-Reid K, George Charlton T, Chen M, Logan A, Ahmed M, Locke I, Sharma B, Doran S, Orton M, Bunce C, Power D, Ahmad S, Chan K, Ng P, Toshner R, Yasar B, Conibear J, Murphy R, Newsom-Davis T, Goodley P, Evison M, Yousaf N, Bitar G, McDonald F, Blackledge M, Aboagye E, Lee R. Hindocha S, et al. Among authors: power d. Radiother Oncol. 2024 Jun;195:110266. doi: 10.1016/j.radonc.2024.110266. Epub 2024 Apr 4. Radiother Oncol. 2024. PMID: 38582181 Free article.
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Pinato DJ, et al. Among authors: power d. JAMA Oncol. 2019 Dec 1;5(12):1774-1778. doi: 10.1001/jamaoncol.2019.2785. JAMA Oncol. 2019. PMID: 31513236 Free PMC article.
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Pinato DJ, Urus H, Newsom-Davis T, Du Parcq P, Belessiotis K, Mapara L, Gupta N, Power D, Weir J, Wong CN, Ratnakumaran RP, Dominy K, Khorashad J, Bower M. Pinato DJ, et al. Among authors: power d. J Immunother. 2020 Feb/Mar;43(2):53-56. doi: 10.1097/CJI.0000000000000295. J Immunother. 2020. PMID: 31567705 Free article.
1,098 results